Global Amyloidosis Therapeutics Market Size By Type (AG-10, ALN-ANG), By Application (AL amyloidosis, AA amyloidoses), By Region, And Segment Forecasts, 2023 to 2032

The Global Amyloidosis Therapeutics Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 9.6 billion by 2031, growing at a CAGR of 11.2% during the forecast period of 2023–2031. Amyloidosis, a rare and potentially life-threatening condition caused by the abnormal buildup of amyloid proteins, has witnessed a rising prevalence globally. This growing burden, coupled with heightened disease awareness, increased diagnostic rates, and significant advancements in targeted drug therapies, is driving the market forward. Expanding clinical research efforts and orphan drug designations have further catalyzed innovation, attracting investments from pharmaceutical giants and biotech firms.

Drivers:

1. Increasing Prevalence and Diagnosis Rates

With greater awareness and advancements in diagnostic imaging and biopsy techniques, amyloidosis is being detected more frequently and at earlier stages, boosting therapeutic demand.

2. Expansion of Orphan Drug Development

Regulatory incentives for rare diseases are encouraging pharmaceutical firms to invest in the development of amyloidosis treatments. Orphan drug designations lead to faster approval timelines, tax benefits, and market exclusivity.

3. Advances in RNA-based and Targeted Therapies

The emergence of RNA interference (RNAi) therapies, monoclonal antibodies, and gene-silencing drugs has transformed treatment paradigms for transthyretin (ATTR) amyloidosis and other subtypes.

Restraints:

1. High Cost of Treatment

Amyloidosis therapies, especially newer agents, are often costly due to complex development processes and limited patient populations, making access a challenge in low-income settings.

2. Limited Awareness Among Primary Care Providers

In many regions, amyloidosis remains underdiagnosed due to limited physician awareness, especially outside specialized medical centers, slowing patient access to timely treatment.

Opportunity:

1. Expansion in Emerging Markets

Growing investments in healthcare infrastructure and rare disease diagnostics in Asia-Pacific and Latin America present untapped growth potential for amyloidosis drug developers.

2. Strategic Collaborations and Pipeline Innovation

Collaborations between academic institutions, pharma companies, and biotech startups are accelerating R&D, leading to new treatment options and personalized therapy approaches.

Market by System Type Insights:

By system type, the Transthyretin Amyloidosis (ATTR) segment held the largest market share in 2023, driven by the successful commercialization of RNA-based drugs such as patisiran and inotersen. ATTR is the most targeted subtype due to its prevalence and drug responsiveness. The AL Amyloidosis segment is also gaining traction, supported by the use of chemotherapy agents and proteasome inhibitors like bortezomib.

Market by End-use Insights:

Hospitals and Specialty Clinics accounted for the largest end-use segment in 2023, reflecting their central role in diagnosing and managing complex rare diseases like amyloidosis. These centers house the specialized expertise and facilities required for treatment administration and monitoring. The home healthcare segment is expected to grow rapidly due to the increasing availability of oral and injectable therapies suitable for outpatient use.

Market by Regional Insights:

North America led the global amyloidosis therapeutics market in 2023, owing to robust R&D activities, favorable reimbursement policies, and the presence of major pharmaceutical companies. Europe followed, with a strong clinical trial network and supportive regulatory environment. Asia-Pacific is forecasted to grow at the highest CAGR due to improved access to diagnostics, rising healthcare expenditure, and increasing awareness in countries like China, India, and Japan.

Competitive Scenario:

Key players in the Global Amyloidosis Therapeutics Market include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Janssen Pharmaceuticals (Johnson & Johnson), Takeda Pharmaceutical Company Limited, Prothena Corporation, Alexion Pharmaceuticals, and BridgeBio Pharma. These companies are leveraging breakthrough drug platforms, expanding their clinical pipelines, and engaging in licensing deals to bolster their market presence.

Scope of Work – Global Amyloidosis Therapeutics Market

Key Market Developments:

2023: Alnylam Pharmaceuticals expanded its therapeutic portfolio with late-stage trials for vutrisiran, a next-generation RNAi therapeutic for ATTR amyloidosis.

2024: Pfizer received FDA approval for tafamidis in additional ATTR subtypes, expanding its market footprint.

2025: Ionis Pharmaceuticals initiated a global Phase 3 trial for a novel antisense oligonucleotide therapy for hereditary ATTR.

FAQs:

What is the current market size of the Global Amyloidosis Therapeutics Market?

The market size was valued at USD 4.1 billion in 2023.

What is the major growth driver of the Global Amyloidosis Therapeutics Market?

The key driver is the increasing prevalence of amyloidosis coupled with advancements in targeted and RNA-based therapies.

Which is the largest region during the forecast period in the Global Amyloidosis Therapeutics Market?

North America is expected to remain the largest regional market through 2031.

Which segment accounted for the largest market share in Global Amyloidosis Therapeutics Market?

The Transthyretin Amyloidosis (ATTR) segment held the largest share in 2023.

Who are the key market players in the Global Amyloidosis Therapeutics Market?

Major players include Pfizer, Alnylam, Ionis Pharmaceuticals, Takeda, Janssen, and Prothena.